Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data demonstrating that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.
KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration for patients with gene mutation-agnostic retinitis pigmentosa. This new data suggests potential broader applications of the ion channel modulator platform beyond retinal diseases. The company noted that the results provide a strong rationale for further investigation of KIO-300 in epilepsy indications.
The study utilized an ex vivo model of temporal lobe epilepsy, a common and often treatment-resistant form of epilepsy. Treatment with KIO-300 resulted in a significant reduction in epileptiform activity, which is characterized by abnormal electrical discharges in the brain. These discharges are a hallmark of seizure activity, and their suppression indicates potential anticonvulsant properties.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. Their lead candidate, KIO-301, is a molecular photoswitch designed to restore vision in patients with inherited or age-related retinal degeneration. The company also has KIO-104, a next-generation, non-steroidal, immuno-modulatory small molecule inhibitor of DHODH for macular edema due to retinal inflammation. This new data from the epilepsy model could expand the company's pipeline into neurology.
The Epilepsy Foundation Pipeline Conference is a key venue for presenting emerging therapies for epilepsy. By presenting these data, Kiora is signaling its interest in exploring neurological applications for its ion channel modulator technology. The company expects to continue evaluating KIO-300 and related compounds in additional preclinical models to support progression toward clinical development.
For more information, visit Kiora Pharmaceuticals' website.
